Teacher Retirement System of Texas Has $4.57 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Teacher Retirement System of Texas lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 14.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,945 shares of the biotechnology company’s stock after buying an additional 1,626 shares during the period. Teacher Retirement System of Texas’ holdings in United Therapeutics were worth $4,568,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in UTHR. Pathstone Holdings LLC boosted its stake in United Therapeutics by 4.1% in the 3rd quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company’s stock worth $1,476,000 after purchasing an additional 163 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of United Therapeutics during the third quarter worth about $344,000. PNC Financial Services Group Inc. raised its position in United Therapeutics by 14.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,179 shares of the biotechnology company’s stock valued at $1,139,000 after buying an additional 412 shares during the last quarter. Cerity Partners LLC lifted its stake in United Therapeutics by 82.1% in the 3rd quarter. Cerity Partners LLC now owns 8,886 shares of the biotechnology company’s stock valued at $3,184,000 after acquiring an additional 4,005 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in shares of United Therapeutics by 26.1% during the 3rd quarter. Daiwa Securities Group Inc. now owns 4,119 shares of the biotechnology company’s stock worth $1,476,000 after acquiring an additional 852 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 80,255 shares of company stock valued at $28,995,021. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $319.86 on Tuesday. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The company has a market capitalization of $14.37 billion, a price-to-earnings ratio of 14.05, a PEG ratio of 0.97 and a beta of 0.64. The company has a 50-day simple moving average of $344.24 and a 200 day simple moving average of $356.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the business earned $4.36 EPS. Sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the topic of a number of research reports. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.